New Wave Wealth Advisors LLC Takes $105,000 Position in Insulet Co. (NASDAQ:PODD)

New Wave Wealth Advisors LLC bought a new position in Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 401 shares of the medical instruments supplier’s stock, valued at approximately $105,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC grew its position in shares of Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after buying an additional 42 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after acquiring an additional 43 shares in the last quarter. Glenmede Trust Co. NA boosted its holdings in Insulet by 2.3% in the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after acquiring an additional 47 shares in the last quarter. Graypoint LLC increased its position in Insulet by 5.3% during the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 47 shares during the period. Finally, Wedmont Private Capital raised its holdings in Insulet by 3.5% in the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock worth $326,000 after purchasing an additional 48 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Citigroup boosted their price target on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Barclays upped their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. JPMorgan Chase & Co. raised their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Wells Fargo & Company increased their price objective on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, BTIG Research boosted their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $272.81.

Insulet Trading Down 0.6 %

Shares of NASDAQ PODD opened at $278.38 on Friday. The firm’s 50 day moving average price is $268.69 and its 200-day moving average price is $237.96. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $286.39. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company has a market cap of $19.53 billion, a PE ratio of 47.67, a P/E/G ratio of 3.48 and a beta of 1.22.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.13. The business had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same period in the prior year, the firm posted $0.71 EPS. On average, equities research analysts expect that Insulet Co. will post 3.22 EPS for the current fiscal year.

Insider Activity at Insulet

In other news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.